Introduction
============

X-ray computed tomography (CT) is one of the most powerful and widely used imaging modalities in modern clinical practice. CT provides non-invasive three-dimensional imaging capabilities at lower cost and higher spatial and temporal resolution than other imaging modalities such as MRI and PET ([@B103]). CT imaging can reveal a patient's anatomy in exquisite detail and is extremely useful in the diagnosis of a wide variety of diseases. CT systems with high resolution (also known as micro-CT systems) have been developed over the last few decades and have been used with great success in small animal studies. With micro-CT, animals can be non-invasively imaged *in vivo* multiple times over the course of a preclinical study, which significantly decreases the number of animals required compared to methods requiring *ex vivo* analysis. Additionally, the continued development of micro-CT can help to test and optimize imaging advances for translation to clinical CT. This review provides an overview of micro-CT imaging principles and applications of micro-CT in preclinical small animal studies, with a special emphasis on the use of nanoparticle contrast agents and spectral imaging methods that could serve well in drug discovery and pharmacological research.

Micro-Ct Imaging Principles
===========================

Imaging System
--------------

A CT system consists of an x-ray source and x-ray detectors, between which the subject is placed. In clinical CT, the x-ray source and detectors rotate around the subject to produce projections of x-ray attenuation through the body at many different angles. For micro-CT, the x-ray source and detectors may also be static, while the small animal is rotated between them. The x-ray projections acquired at each angle of rotation are then used to reconstruct tomographic images, which are visualized as 2D slices or 3D volumes of the specimen. The most common reconstruction method for micro-CT is a cone-beam implementation of filtered back projection ([@B61]). A schematic of a micro-CT system and reconstruction process is shown in **Figure [1](#F1){ref-type="fig"}.**

![**Schematic of a micro-CT system.** Multiple x-ray projections are acquired over a 360° rotation around the subject. These individual x-ray projections are then reconstructed to produce 2D cross-sectional images and 3D volumes.](fphar-06-00256-g001){#F1}

X-ray Generation
----------------

X-rays are generated by accelerating electrons across a high voltage to collide with an anode composed of a high atomic number, high melting point material (commonly tungsten). Interactions between the electrons and the tungsten anode lead to the production of x-rays with a broad energy spectrum. The maximum energy of the x-ray spectrum is determined by the voltage applied in the x-ray tube. As tube voltage increases, the mean x-ray energy and number of photons produced both increase. This is demonstrated in **Figure [2A](#F2){ref-type="fig"}** for a tungsten anode operating at two different voltages: 80 and 140 kV. The energy of the produced x-rays is an important determinant of their absorption by a given material. This energy spectrum can be modified by filtration through metal filters. Filtration is primarily used to increase the mean energy of the x-ray spectrum by removing low energy photons. Filtration can be used to both reduce radiation dose and improve image quality, and filtration can be optimized depending on the imaging task ([@B89]). Micro-CT x-ray tubes differ from clinical x-ray tubes in that they usually have a much smaller focal spot (area where the electron beam interacts with the anode), which reduces the source function blur (i.e., penumbra blurring) and thereby greatly improves the maximum image resolution. This increased resolution is necessary for imaging small animals which have much smaller features than humans.

![**X-ray production and attenuation.** **(A)** X-ray energy spectra produced at two different tube voltages: 80 and 140 kV. Both the number of photons produced and the mean energy of the spectrum increases with higher voltage. **(B)** X-ray attenuation as a function of x-ray energy for multiple materials. In general, the x-ray attenuation rapidly drops with increasing x-ray energy. At the K-edge of each material, there is a sharp rise in attenuation due to the photoelectric absorption at that energy.](fphar-06-00256-g002){#F2}

X-ray Attenuation
-----------------

X-rays travel from the focal point of the x-ray tube, through the subject, and on to the x-ray detector. The x-ray detector measures the relative amount of x-rays absorbed by the subject at any given position. X-ray attenuation is given by
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where I is the intensity of the x-rays transmitted through the subject, I~0~ is the original intensity of the x-rays incident on the object, μ is the linear attenuation coefficient of the object, and x is the thickness of the object. Therefore, absorption of x-rays by a material is dependent on the thickness of the material and on the material-dependent attenuation coefficient. Diagnostic x-rays can be absorbed by a material via two primary mechanisms: compton scattering and the photoelectric effect.

Compton scattering occurs when an x-ray photon collides with an outer shell electron within the subject. Upon collision, the electron absorbs a portion of the x-ray energy and is ejected from the atom. The x-ray photon is deflected from its original direction and loses some energy. This scattering can occur in all directions and can lead to noise at the detector. The amount of Compton scattering that occurs within an object depends primarily on the energy of the incident x-ray photon and the density of the object. Compton scattering decreases slightly with increasing photon energy, so higher energy x-rays are better able to pass through a patient without attenuation. The density of outer shell electrons increases with the mass density of a material, so denser materials tend to have more Compton scattering and therefore more x-ray attenuation.

The photoelectric effect occurs when an x-ray photon transfers all of its energy to an inner shell electron within the subject. This electron is ejected from the atom and its vacancy is subsequently filled by an outer-shell electron, which leads to the release of a secondary photon. The photoelectric effect is highly dependent on both the energy of the incident x-ray and the atomic weight of the object. The photoelectric effect is strongest when the x-ray energy matches the binding energy of the inner-shell electrons. As x-ray energy increases, the likelihood of the photoelectric effect drops rapidly, proportional to the inverse cube of the x-ray energy (1/E^3^). If the x-ray energy is below the energy of a particular electron shell, then none of those electrons can participate in the photoelectric effect because the x-ray does not have enough energy to overcome the electron binding energy. This leads to the K-edge effect, where the probability of absorption due to the photoelectric effect jumps abruptly as the x-ray energy increases above the K-shell electron binding energy. The photoelectric effect is also proportional to the cube of a material's atomic number (Z^3^), so high atomic weight materials exhibit a much stronger photoelectric effect than low atomic weight materials. This is why contrast agents for CT traditionally include high atomic weight elements (e.g., iodine, barium). The K-edge effect is shown in **Figure [2B](#F2){ref-type="fig"}**, which demonstrates the relative probability of x-ray photon attenuation at different x-ray energies for several high Z materials such as iodine, gold, barium, gadolinium, bismuth.

Applications Of Non-Contrast-Enhanced Micro-Ct
==============================================

Micro-CT images only demonstrate high contrast when there are large differences between material densities (Compton scattering) or atomic weights (photoelectric effect) within the patient. In the case of soft tissue imaging, there is very little natural contrast so an exogenous high atomic weight contrast agent must be administered for effective imaging ([@B190]). However, non-contrast-enhanced micro-CT performs well for bone and lung imaging, both of which have high inherent contrast in the absence of exogenous contrast agents.

Bone Imaging
------------

Micro-CT is well-suited for bone imaging because of the natural contrast between bone and soft tissues, which is due to the high effective atomic weight of bone. This makes micro-CT extremely valuable for non-invasive, high-resolution bone imaging without the need of an exogenous contrast agent. Bone imaging was one of the very first common applications of micro-CT for small animal imaging ([@B62]; [@B102]). Micro-CT can accurately quantify a variety of bone parameters, including cross-sectional area, cortical thickness, bone mineral density, bone volume, bone surface ratio, and trabecular thickness ([@B33]). Structural micro-CT studies have examined bone architecture ([@B181]; [@B87]), bone remodeling ([@B52]; [@B48]), and osteoarthritis ([@B8]; [@B127]). Micro-CT has also been used to monitor bone healing after treatment with basic fibroblast growth factor ([@B189]), vascular endothelial growth factor gene therapy ([@B114]), or stem cell therapy ([@B111]). Micro-CT can also be used to longitudinally track bone loss and structural changes following radiation therapy and bone marrow transplantation ([@B57]) or after spinal cord injury ([@B94]). In the case of osteoporosis, micro-CT measurements have been used to study disease progression after ovariectomy ([@B108]) or immobilization ([@B107]). Micro-CT has also been used to study early bone development and growth ([@B73]). Additionally, micro-CT has been used extensively in studies of bone regeneration ([@B177]) and bone tissue engineering ([@B119]; [@B85]). In these cases, micro-CT can quantify mineral content, porosity, and connectivity, as well as accurately determine three-dimensional structures. **Figure [3](#F3){ref-type="fig"}** illustrates the use of micro-CT to evaluate healing of a tibial bone defect after treatment with an osteoinductive gel scaffold ([@B158]). This study shows the ability of micro-CT to produce both 2D cross-sectional bone images as well 3D reconstructions of entire bones. Within the 3D reconstructions, bone microarchitecture is clearly visualized.

![**Tibial bone defect micro-CT imaging.** **(A)** Axial micro-CT cross-sections and **(B)** 3D reconstructions of tibial bone defects after treatment with an osteoinductive gel scaffold. Longitudinal imaging was performed up to 25 weeks. Addition of the treatment gel significantly improves healing of the bone defect. Reprinted from ([@B158]) under the Creative Commons Attribution License.](fphar-06-00256-g003){#F3}

Lung Imaging
------------

The large difference in density between air-filled lungs and soft tissues creates high contrast for lung imaging, which makes CT an extremely useful modality for studying the lung. The primary difficulty in imaging the lungs is respiratory motion. Small animal respiratory rates are 3--4 times the average human respiratory rate, so completing an entire scan between breaths is not practical. Instead, various gating strategies are used which allow researchers to acquire each projection at the same stage in the respiratory cycle, so that there is only minimal motion from one projection to the next. One of the most effective methods of respiratory gating is to intubate the animal and control the respiration by mechanical ventilation ([@B84]; [@B137]). This allows projections to be acquired at exactly the same point in each respiratory cycle. For a less invasive approach, the respirations of a freely breathing animal can be monitored using a pressure transducer. The x-ray projections can then be acquired automatically at the same point in the measured respiratory cycle ([@B17]). This method does not perfectly eliminate respiratory motion, but it is much less invasive than mechanical ventilation and can still resolve features down to ∼150 microns ([@B137]). Retrospective gating is also possible, in which many projections are acquired rapidly and sorted post-acquisition according to phase of the respiratory cycle. Subsequently, these sorted projections are used for the reconstruction of tomographic images corresponding to each phase of the respiratory cycle ([@B66]).

Micro-CT with respiratory gating has been used to study a wide variety of lung diseases. Micro-CT can be used to longitudinally monitor mice for the presence of lung metastases ([@B116]) as well as follow the growth of lung tumors ([@B86]; [@B138]; [@B112]; [@B156]). The treatment efficacy of chemotherapy ([@B176]) or radiation therapy ([@B146], [@B147]; [@B104]) on lung tumors can be measured using micro-CT, and lung injury resulting from radiation therapy can also be assessed ([@B159]). In addition to tumor characterization, micro-CT is also useful for imaging diseases of the lung parenchyma. Mouse models of emphysema created by intra-tracheal instillation of elastase ([@B149]; [@B10]; [@B53]; [@B134]) or exposure to cigar smoke ([@B161]) have been developed and characterized by micro-CT. In emphysema, CT values decrease compared to normal lung due to the loss of soft tissue parenchyma and increased air-trapping. A mouse model of bleomycin-induced lung fibrosis has also been studied extensively by micro-CT ([@B168], [@B169]; [@B53]) and this model has been used with micro-CT for the preclinical evaluation of drug efficacy ([@B166]; [@B39]; [@B193]). In fibrosis, CT values increase due to an expansion of the parenchyma tissue. Lung compliance and lung volume, which are important factors in both emphysema and fibrosis, can also be measured by micro-CT. Animals are mechanically ventilated at multiple pressures and the lung volume at each pressure is measured. The resulting lung pressure-volume curve can be used to calculate lung compliance ([@B72]; [@B168]). **Figure [4](#F4){ref-type="fig"}** shows an example of automatic quantification of lung air volumes using micro-CT in normal mice and in mice with bleomycin-induced fibrosis ([@B53]). Micro-CT has also been used to detect chronic silicosis ([@B11]) and acute respiratory distress syndrome ([@B180]).

![**Automated analysis of lung air volumes for a normal mouse and a mouse with lung fibrosis.** CT cross-sections of the lungs are thresholded to include only those voxels which primarily contain air. These binary images are then converted to 3D volumes to visualize and quantify the aerated lung volumes. The fibrotic lung has significantly reduced air volume compared to the normal lung. Reprinted from ([@B53]) under the Creative Commons Attribution License.](fphar-06-00256-g004){#F4}

Micro-Ct Contrast Agents
========================

Because of the lack of inherent contrast for soft tissue imaging, the majority of CT scans make use of high atomic weight contrast agents. In current clinical practice, iodine is the most commonly used element for intravascular CT contrast. Iodine contrast agents are made up of water-soluble aromatic iodinated compounds. These compounds provide effective contrast due to their high atomic number, which produces a strong photoelectric effect. Because CT is relatively insensitive to contrast, high concentrations of contrast agent (up to 400 mg iodine/mL) must be injected in order to produce adequate image enhancement. Clinical CT contrast agents are generally safe, but severe adverse reactions sometimes occur. These adverse reactions are generally divided into two types: allergic reactions and contrast-induced nephropathy (CIN). CIN occurs due to the high osmolality and viscosity of clinical contrast agents and is more common in patients with chronic renal disease ([@B136]; [@B173]; [@B182]). Iodinated contrast agents are rapidly cleared from the bloodstream by the kidneys ([@B32]), so there is only a very short window for imaging after injection. Additionally, these agents quickly distribute from the intravascular to the extravascular space throughout the body. Initially, this provides useful contrast, but after a short time this nonspecific uptake leads to uniform enhancement throughout most of the body. Development and optimization of these small molecule contrast agents continues in order to address some of these limitations, but no breakthroughs have occurred in clinical contrast agents for many years ([@B123]). This lack of progress is primarily due to the significant hurdle of developing high atomic weight agents that simultaneously demonstrate low toxicity, high efficacy, and low cost.

For small animal imaging, the use of clinical contrast agents is particularly difficult. Small animals have much higher renal clearance rates than humans, so injected contrast agents are rapidly excreted. This can be illustrated for the case of a mouse. In the average adult mouse, blood volume is approximately 1.5--2.0 mL ([@B56]), and the glomerular filtration rate (the volume of plasma filtered by the kidneys per time) is approximately 0.4 mL/s ([@B36]). Therefore, the whole mouse blood volume is filtered by the kidneys in less than 5 s. Consistent with this filtration rate, it has been shown that clinical iodine contrast agents drop to undetectable levels in the bloodstream within 4 s of injection in a mouse ([@B120]). This rapid clearance of contrast agent severely limits the useful application of clinical contrast agents in small animals.

To overcome the rapid clearance of traditional contrast agents, blood pool contrast agents have been developed which exhibit prolonged blood residence time and stable enhancement for minutes to hours. Blood pool agents are made up of a wide variety of high molecular weight compounds or nanoparticles that avoid renal clearance due to their large size. Iodine-based blood pool agents include iodine-containing polymers ([@B67]; [@B14]), micelles ([@B175]; [@B174]), emulsions ([@B55]; [@B83]; [@B113]), and liposomes ([@B105]; [@B148]; [@B132]; [@B68]). A schematic demonstrating the configuration of several iodine-containing nanoparticle agents is shown in **Figure [5](#F5){ref-type="fig"}.** Historically, these iodine nanoparticles have been the most used contrast agents for micro-CT imaging. The development and use of these iodine-containing blood pool contrast agents have been reviewed elsewhere ([@B82]; [@B7]; [@B45]; [@B115]). Some iodine-containing blood pool agents are commercially available for small animal research, including *Fenestra*^®^ (MediLumine, Montreal, QC, Canada) and *Exia^TM^* (Binitio Biomedical, Inc., Ottawa, ON, Canada), and *Exitron^TM^ P* (Miltenyi Biotec, San Diego, CA, USA).

![**Iodine-containing nanoparticles.** **(A)** Representation of individual amphiphilic lipids that can be incorporated into nanoparticles. **(B)** Representation of several configurations of self-assembling nanoparticles based on amphiphilic lipids. Iodine can be incorporated into the hydrophobic portion of the micelle, within the non-polar core of an emulsion, or within the aqueous core of liposomes. Reprinted with permission from ([@B133]).](fphar-06-00256-g005){#F5}

Over the past several years, metal nanoparticle contrast agents have been developed incorporating a wide variety of elements. The most commonly used metal nanoparticles for micro-CT consist of gold. Gold nanoparticles produce greater CT enhancement than iodinated contrast agents because of the high atomic number of gold (*Z* = 79) compared to iodine (*Z* = 53). Gold nanoparticles are particularly promising for *in vivo* imaging applications because gold is extremely inert and gold nanoparticles can be readily modified with surface-linked molecules to render them biocompatible ([@B117]). Bismuth is another promising element for use as contrast agent because it is plentiful, inexpensive, and has a high atomic number (*Z* = 83). Multiple formulations of bismuth nanoparticles have been proposed for use as CT contrast agents ([@B150]; [@B1]; [@B145]; [@B171]). Nanoparticles for micro-CT have also been developed using other metals, including bismuth, barium, tantalum, silver, gadolinium, ytterbium, and thorium ([@B91]). Some metal nanoparticle contrast agents are commercially available, including the gold nanoparticle agent AuroVist^TM^ (Nanoprobes, Inc., Yaphank, NY, USA) and the barium nanoparticle agent *Exitron^TM^ Nano* (Miltenyi Biotec).

Surface conjugation is important for nanoparticle contrast agents, because bare nanoparticles adsorb serum proteins and are readily recognized and cleared by the immune system. A variety of molecules can be added to the nanoparticle surface to decrease nanoparticle clearance, but the most common modification strategy is the addition of polyethylene glycol (PEG; [@B97]). Surface PEGylation significantly increases nanoparticles' blood residence time, which allows them to be used as blood pool contrast agents. Nanoparticles' blood residence time and biodistribution are also heavily influenced by their size and shape, with smaller nanoparticles tending to have longer blood residence times.

Applications Of Contrast-Enhanced Micro-Ct
==========================================

The development of nanoparticle contrast agents has opened the door for many exciting applications in small animal imaging. While imaging applications using low molecular weight contrast agents have been limited, blood pool contrast agents have now been used for a wide range of imaging applications. Important modern applications for contrast-enhanced micro-CT in small animals include imaging of the vasculature, heart, abdomen and tumors. Current micro-CT contrast agent research is now focused on developing agents with active targeting, multi-modal, or theranostic capabilities.

Vascular Imaging
----------------

Vascular imaging for micro-CT is done primarily using blood pool contrast agents. Micro-CT scan times must be longer than clinical CT scan times due to the requirement for much higher resolution. Higher resolution implies a need for more x-ray flux, which is achieved with a longer integration time per projection. Early micro-CT scanners required up to an hour to complete a scan. In these cases, low molecular weight contrast agents could not be used for vascular imaging, as they would be cleared from the bloodstream long before the image acquisition was completed. For current micro-CT scanners, scan times of under a minute are now possible. Using these fast protocols, low molecular weight contrast agents have been successfully used for vascular imaging ([@B99]; [@B23]; [@B163]). However, these contrast agents must be either repeatedly or continuously administered over the course of a scan to achieve a constant level of vascular enhancement. This increases the difficulty of imaging and may significantly increase the injected dose of contrast agent. As an alternative to low molecular weight contrast agents, blood pool contrast agents have been successfully used for a variety of vascular applications, including measurements of vascular morphology, diameter, and branching ([@B178]), imaging pulmonary vasculature ([@B95]), imaging hepatic vasculature ([@B40]), imaging tumor vasculature ([@B23]; [@B71]), and measuring vascular permeability ([@B109]). By providing a constant level of enhancement within the vasculature over a prolonged period of time (minutes to hours), these contrast agents simplify the acquisition of vascular images using micro-CT and allow for a wider range of imaging protocols to be used. **Figure [6](#F6){ref-type="fig"}** shows an example of vascular imaging. In this study, micro-CT was used with a liposomal iodine contrast agent in order to study the vasculature associated with primary soft tissue sarcomas of the hindlimb ([@B129]).

![**Coronal maximum intensity projection of intravascular iodine in a mouse with a soft-tissue sarcoma in the right hindlimb.** Micro-CT imaging (88 μm voxel size) was performed immediately after injection of a liposomal iodine contrast agent.](fphar-06-00256-g006){#F6}

Cardiac Imaging
---------------

Cardiac imaging is challenging in small animals due to their rapid heart rate (∼600 bpm for mice). Like respiratory gating (see Lung Imaging), cardiac gating can be used to minimize artifacts due to cardiac motion in the resulting CT images. Cardiac gating can be performed either prospectively ([@B16], [@B18], [@B21]; [@B65]; [@B74]) or retrospectively ([@B26]; [@B170]; [@B18], [@B22]; [@B12]). In both cases, the ECG of the animal is continuously monitored. In prospective gating, each projection is triggered at a pre-defined point of the cardiac cycle, so that the heart is in the same position in each of the projections. In retrospective gating, projections are acquired rapidly over several rotations and then the timing of the images is compared to the ECG tracing. Each of the images is sorted into projections belonging to different points in the cardiac cycle. Each set of projections can then be compiled together for tomographic reconstruction. Retrospective gating is much more rapid, but produces an irregular angular distribution of projections, which can cause artifacts during the reconstruction process. Because prospectively gated images are acquired over many cardiac cycles, they require several minutes to perform. Many cardiac imaging protocols incorporate both respiratory and cardiac gating to minimize overall thoracic motion during the scan ([@B17]). We note that intrinsic retrospective gating can also be implemented with cardiac and respiratory motion signals derived from information within each of the acquired projections, thus avoiding the complications of having ECG or respiratory sensors attached to the mouse ([@B25]; [@B96]; [@B106]).

For all cardiac imaging, contrast agents are necessary to differentiate the myocardium from the heart lumen. Because cardiac-gated scans can require several minutes to perform, enhancement of the blood within the heart must remain constant for a prolonged period of time to produce high quality scans. Such imaging is possible with low molecular weight contrast agents by using continuous administration or repeated injections ([@B162]), but the vast majority of studies have made use of blood pool contrast agents, which make cardiac-gated CT protocols practical. Because images can be acquired over multiple phases of the cardiac cycle, cardiac micro-CT can produce 4D images of the beating heart. These datasets can be used to measure cardiac function, including ventricular volumes, stroke volume, ejection fraction, wall motion, and cardiac output ([@B16], [@B24], [@B19], [@B21]; [@B184]). Measurements of cardiac function by micro-CT can be used to evaluate the effect of drugs in preclinical studies. Cardiac micro-CT has been used to measure changes in cardiac function as a result of dobutamine-induced cardiac stress ([@B22]), as shown in **Figure [7A](#F7){ref-type="fig"}.** Cardiac micro-CT can also be used to longitudinally measure changes in cardiac function over time. For example, left ventricular remodeling following a coronary ligation-induced myocardial infarction has been tracked by micro-CT ([@B167]). Measurements of cardiac function and infarct size have also been performed in coronary ligation mouse models using either a combination of blood pool agent (Fenestra VC) and a low molecular contrast agent ([@B135]) or a blood pool contrast agent (Exia 160) which shows specific uptake in myocardium ([@B12]). An example of micro-CT imaging of myocardial infarction using a delayed hyperenhancement protocol ([@B135]) is shown in **Figure [7B](#F7){ref-type="fig"}.**

![**Cardiac micro-CT imaging.** **(A)** Coronal micro-CT images through the left ventricle of a rat showing the heart in systole (left) and diastole (right) with and without the administration of dobutamine (10 μg/kg/min). End systolic volume is significantly decreased and stroke volume and cardiac output are both significantly increased. End diastolic volume is relatively unchanged after administration of dobutamine. **(B)** An axial image showing myocardial infarction in a rat using delayed hyper enhancement. The yellow arrows show the boundaries of the region of myocardial infarction.](fphar-06-00256-g007){#F7}

Liver and Spleen Imaging
------------------------

Blood-pool contrast agents, which avoid renal clearance due to their large size (\>6 nm), are eventually cleared from the bloodstream by phagocytic cells in the reticuloendothelial system ([@B130]). This clearance occurs primarily in the liver and spleen, which leads to accumulation of contrast in those organs over time. This leads to high enhancement of these organs for liver and spleen-specific imaging. One of the most commonly used micro-CT contrast agents, Fenestra LC, is composed of iodinated phospholipids which are recognized by the ApoE receptor on hepatocytes and internalized in the liver, which provides additional specificity for liver imaging. Because these blood pool contrast agents get taken up by normal-functioning liver and spleen, they can be used to identify necrotic regions ([@B40]), liver tumors ([@B3]; [@B131]; [@B54]; [@B71]; [@B100]; [@B29]), and spleen tumors ([@B3]), as well as to measure organ volume, quantify hepatic necrosis ([@B179]), and determine liver anatomy ([@B64]). **Figure [8](#F8){ref-type="fig"}** shows longitudinal imaging of liver metastases as they increase in size over time following a single injection of nanoparticle contrast agent ([@B29]).

![**Longitudinal micro-CT imaging of liver metastases in a mouse following injection of a nanoparticle contrast agent.** A single mouse is shown at 9 days **(A)**, 12 days **(B)**, 14 days **(C)**, and 19 days **(D)** after intrasplenic injection of tumor cells. Normal liver tissue is highly enhancing due to nanoparticle uptake, while the tumor regions show no enhancement. The enhancement remains high within the normal liver over the entire course of the experiment. By day 19, metastatic tumors take up the majority of the liver volume. Reprinted from ([@B29]) under the Creative Commons Attribution License.](fphar-06-00256-g008){#F8}

Cancer Imaging
--------------

Because tumors generally have the same density as their surrounding tissues, contrast agents are necessary for tumor identification and characterization by micro-CT. The vast majority of cancer imaging studies have been performed using blood pool nanoparticle contrast agents. Nanoparticles tend to accumulate in tumors due to the enhanced permeability and retention (EPR) effect ([@B125]; [@B124]). Rapid angiogenesis within a tumor leads to the development of immature, poorly organized, leaky vasculature. Gaps in this leaky vasculature are large enough that nanoparticles (up to 200--300 nm) can readily extravasate into the tumor tissue. Tumors also tend to have very poorly developed lymphatic drainage, so the nanoparticles are not cleared from the tumor once they extravasate. This effect leads to the gradual passive accumulation of nanoparticles in the tumor perivascular space over the course of hours to days. EPR has been widely exploited for both tumor imaging and therapy using nanoparticle agents.

Using micro-CT, dynamic biodistribution of contrast agent within small animal tumor models can be tracked. A liposomal iodine contrast agent was used in a rabbit tumor model for contrast agent tracking and biodistribution analysis ([@B191]). Quantitative analysis was performed to determine the percent contrast agent uptake within each organ, including the tumor. Liposomal iodine was also used in two mouse models of breast cancer to demonstrate dynamic changes in enhancement within tumor vasculature and tumor parenchyma ([@B160]; [@B68]). Immediately after injection, the contrast agent is entirely intravascular, with no significant enhancement within the tumor tissue. This early phase allows for the analysis of tumor vascular morphology, location, and density. After the contrast agent was cleared from the bloodstream, late phase imaging was performed to demonstrate passive accumulation of the contrast agent in the tumors due to EPR. The tumors showed heterogeneous enhancement throughout their volumes, demonstrating spatial heterogeneity in tumor perfusion and vascular permeability. **Figure [9](#F9){ref-type="fig"}** shows an example of nanoparticle dynamic biodistribution and tumor accumulation for a mouse injected with liposomal iodine ([@B68]). Immediately after liposome injection, blood vessels are clearly outlined. At later time points, the liposomes accumulate both in the flank tumor and in the liver and spleen. Further studies have been done in mouse xenograft tumor models to carefully map the spatial and temporal distribution of liposome uptake by micro-CT ([@B59]), which has important implications for nanoparticle-based drug delivery. Measurements of tumor vascular density in early phase imaging and total contrast accumulation in late phase imaging have also been used in two mouse models of lung cancer to differentiate between benign and malignant cancer types ([@B15]). Iodine-containing nanoparticle contrast agents have also been used for tumor imaging in two other models of lung cancer ([@B101]; [@B5]) and a mouse model of liver cancer ([@B155]). Gold nanoparticles have also been used for passive tumor targeting in mouse models of breast and brain cancer ([@B79], [@B81]).

![**Longitudinal micro-CT imaging of liposomal iodine biodistribution.** Liposomes slowly accumulate in the subcutaneous tumor, liver, and spleen over the course of 72 h. The white arrow points to the location of the tumor in each image.](fphar-06-00256-g009){#F9}

Active Targeting
----------------

In addition to the passive accumulation of nanoparticles in the reticuloendothelial system or tumors, active targeting of nanoparticles can be accomplished by conjugating specific ligands to the nanoparticle surface which can then link to their binding partners *in vivo* ([@B60]). Typically, these binding partners are cellular receptors or extracellular matrix proteins that are overexpressed in a pathological condition, so binding is specific to the region of pathology. Potential ligands for conjugation to the nanoparticle surface include antibodies, antibody fragments, other proteins, peptides, aptamers, lipids, carbohydrates, and other small molecules. The use of targeted contrast agents for micro-CT has recently been reviewed ([@B115]). Gold nanoparticles have been used extensively for active targeting due to the ease of gold surface modification via gold-thiol bond formation. Gold nanoparticles have been used as a micro-CT contrast agent for the targeting of multiple tumor markers, including Her2 ([@B78]), the gastrin-releasing peptide (GRP) receptor ([@B37]), the epidermal growth factor receptor (EGFR) ([@B151]b), the folic acid receptor (FAR) ([@B183]), and tumor microcalcifications ([@B44]). **Figure [10](#F10){ref-type="fig"}** demonstrates the use of EGFR-antibody conjugated gold nanoparticles to target an EGFR-expressing subcutaneous tumor. Tumor enhancement was significantly increased with targeted gold nanoparticles compared to non-targeted gold nanoparticles (190 HU vs. 78 HU). Gold nanoparticles have also been used for CT imaging of lymph nodes by targeting CD4 ([@B58]), imaging of inflammation by targeting intravascular E-selectin ([@B187]), imaging of atherosclerosis by targeting fibrin ([@B185]), imaging of myocardial scars by targeting collagen ([@B51]), and imaging of other cardiovascular disease ([@B69]). In addition to targeting by the surface conjugation of a ligand, some nanoparticles have inherent targeting abilities due to their nanoparticle chemistry. Gold nanoparticle encapsulated within HDL particles are naturally recognized by HDL receptors and taken up in atherosclerotic plaques ([@B46]). Exia-160 consists of iodinated molecules which can be fully metabolized by the body, and therefore the contrast agent accumulates in metabolically active tissues, including the myocardium and brown adipose tissue. This effect has been used to discriminate between healthy and infarcted myocardium ([@B12]).

![**3D micro-CT reconstructions of mice with EGFR-expressing tumors.** Mice were injected with **(A)** saline, **(B)** non-targeted gold nanoparticles, or **(C)** EGFR-antibody targeted gold nanoparticles. Increased CT enhancement was seen for both types of nanoparticles, but targeted nanoparticles showed significantly higher enhancement than non-targeted controls. Reprinted from with permission from ([@B151])](fphar-06-00256-g010){#F10}

Targeted CT imaging can also be accomplished by labeling cells with nanoparticle contrast agents. Cell labeling with nanoparticles has been successfully used for MRI and other imaging modalities, but has only recently been demonstrated for CT ([@B27]). In this study mesenchymal stem cells were labeled with gold nanoparticles prior to injection into a rat model of depression. Cell migration into depression-related bring regions was successfully tracked up to 1 month post-transplantation using micro-CT. The continued development of CT contrast agents for targeted imaging and cell tracking will improve the specificity of CT imaging for a wide range of pathologies and cell therapies and will make molecular imaging with CT a reality.

Multi-modality Imaging
----------------------

Micro-CT can also be combined with other imaging modalities in order to better study molecular and anatomical information simultaneously. A micro-CT system can be combined with single photon emission computed tomography (SPECT), positron emission tomography (PET), or fluorescence molecular tomography (FMT) into a single unit ([@B70]; [@B118]). SPECT, PET, and FMT are all highly sensitive, so targeted molecular imaging with radio-labeled or fluorescently labeled small molecules or biomolecules is readily accomplished. However, these modalities are all limited by poor spatial resolution and poor anatomical imaging. By combining these systems with micro-CT, high resolution anatomical images can be co-registered with molecular images to produce highly useful datasets. Combining micro-SPECT and micro-PET with micro-CT can also improve the image quality of the resultant SPECT and PET images by allowing for attenuation correction ([@B41]; [@B90]). **Figure [11](#F11){ref-type="fig"}** shows a combined micro-CT/micro-PET image for a tumor-bearing mouse soon after injection of both liposomal iodine and ^18^F-fluorodeoxyglucose (FDG) ([@B20]). The micro-CT image provides high resolution anatomical detail to give context to the tumor signal seen in the micro-PET image.

![**Multi-modal micro-CT/micro-PET imaging.** **(A)** Maximum intensity projection rendered micro-CT image acquired 1 h post-administration of PEGylated liposomal-iodixanol. **(B)** The overlaid PET/CT image shows the metabolically active tumor (green ellipse).](fphar-06-00256-g011){#F11}

A second application of multi-modal imaging which has gained much attention recently is the use of agents that produce contrast for multiple imaging modalities simultaneously. Thus, multiple imaging modalities can be used after injection of a single contrast agent. This helps to improve registration between the different modalities, and increase the amount of information gained from hybrid imaging systems. Many different formulations of multi-modal contrast agents have been developed, and the development of these agents has been reviewed previously ([@B98]). Combined CT/MR contrast agents have been developed using gadolinium chelates conjugated to gold nanoparticles ([@B4]) or gold nanoshells ([@B47]), liposomes containing both gadolinium and iodine-based contrast agents ([@B192]), and iron oxide core nanoparticles surrounded by either a gold shell ([@B35]) or a mesoporous silica shell filled with iodinated oil ([@B188]). A combined CT/SPECT agent has been developed using a dendrimer linked to both iodinated organic molecules and SPECT agent chelators ([@B49]). A combined PET/CT agent has been demonstrated using gold nanoparticles conjugated to both glucose and ^18^F-FDG for targeting of metabolically active tumors ([@B153]; [@B63]). All of these formulations have been successfully tested *in vivo* with multi-modal small animal imaging.

Theranostics
------------

Another exciting topic of current research is the development of theranostic nanoparticles -- nanoparticles that can be used for both therapy and diagnostic imaging. Many nanoparticles used as micro-CT contrast agents can easily be adapted to incorporate therapeutics or act directly as a therapeutic agent themselves. Gold nanoparticles, for example, have the inherent ability to increase the effectiveness of radiation therapy, because they absorb therapeutic x-rays efficiently and then release that energy to the surrounding tissues. This can significantly increase the locally delivered dose in regions of high nanoparticle concentration. This has been used by several groups to effectively treat cancer in multiple animal models ([@B80], [@B75], [@B76], [@B81], [@B77]; [@B93]; [@B142]; [@B186]). Gold nanoparticles also exhibit high absorbance of light at their surface plasmon resonance wavelength, which can be tuned by altering the shape and size of the nanoparticle. For many gold nanoparticle shapes (i.e., nanorods, nanoshells, nanostars), this plasmon resonance occurs in the near infrared region, which is optimal for use with photothermal heating. In photothermal heating, nanoparticles convert laser light into heat, which leads to local hyperthermia. This can be used for tumor ablation when nanoparticles are accumulated within a tumor. The use of nanoparticle for combined CT imaging and photothermal therapy has been recently reviewed ([@B50]). Gold nanorods ([@B88]) and hollow gold nanoshells ([@B142]) have both been used for combined CT imaging, radiation therapy, and photothermal therapy. **Figure [12](#F12){ref-type="fig"}** shows a gold nanostar theranostic probe which was used for CT imaging and photothermal therapy in a mouse model of primary soft tissue sarcoma ([@B121]). This probe showed high tumor accumulation and CT enhancement as well as effective tumor ablation following photothermal therapy. Therapeutics can also be incorporated into nanoparticles by direct conjugation to the nanoparticle surface or by co-encapsulation of the therapeutic with the imaging agent (e.g., within the aqueous core of a liposome). Both methods have been used for the addition of therapeutic radioisotopes or chemotherapy drugs to nanoparticle contrast agents ([@B38]; [@B122]; [@B157]; [@B194]).

![**Theranostic gold nanostars for micro-CT imaging and photothermal therapy.** **(A)** TEM image of gold nanostar (scale bar -- 20 nm). **(B)** Micro-CT axial section through the soft tissue sarcoma on a mouse hindlimb following gold nanostar injection. Green represents gold concentration (windowed from 2 to 10 mg/mL). **(C)** Photothermal therapy after injection of either gold nanostars or saline. The mice receiving gold nanostars showed complete remission of their sarcoma, while the control mice had continued rapid tumor growth.](fphar-06-00256-g012){#F12}

Future Directions -- Spectral Ct
================================

Much effort has been made to overcome the low contrast sensitivity inherent in CT imaging. The primary method, as discussed above, is to add large amounts of an exogenous contrast agent. However, significant developments have also been made in imaging system design which can potentially improve CT image contrast. One of the most promising recent developments in CT has been the use of spectral information to improve contrast discrimination. In traditional CT imaging, the overall attenuation of x-ray intensity is measured by the detector, but the detected x-rays are not spectrally resolved. The spectrum of transmitted x-rays is important because the absorption of x-rays by different materials is highly dependent on x-ray energy, so the transmitted x-ray spectrum depends on what materials are present along the x-ray path. Therefore, there is a significant amount of information that can be gained by including spectral data in the CT reconstruction process. Based on differences in x-ray absorption, multiple materials can be differentiated and quantified within a single scan using spectral CT.

There are two primary methods used to obtain spectral CT data. The first method, dual-energy (DE) CT, uses x-ray sources with two different energy spectra and traditional energy integrating x-ray detectors. The second method uses a single x-ray source but has energy-resolving detectors (photon counting detectors) that can measure the energy of each detected photons. DE CT is currently used clinically and has been successful in improving imaging for a variety of applications ([@B92]; [@B9]; [@B126]; [@B128]; [@B139]; [@B144]; [@B30])

Dual-energy CT
--------------

DE CT can use either a single x-ray source which rapidly switches between two tube voltages or two separate sources (offset from one another by 90°) that each operate at a unique voltage. In either case, x-ray projections are acquired at each rotation angle using both x-ray sources. Additionally, a double-layer or "sandwich" detector is sometimes used to separate low and high energy x-rays. In DE CT, a complete CT dataset is acquired for two different x-ray energy spectra. Most of a patient's body appears the same on both images, because absorption of x-rays by low atomic weight materials, which is primarily due to Compton scattering, is very weakly dependent on x-ray energy. However, the photoelectric effect in high atomic weight materials is highly dependent on x-ray energy. Therefore, the attenuation coefficient of high atomic weight materials (calcium in bone, iodine, gold) will depend on the energy spectrum of the incident x-rays. This effect is particularly pronounced if the two energy spectra fall on either side of the K-edge for one of the materials. Because there is a large increase in attenuation at energies above the K-edge (see **Figure [2B](#F2){ref-type="fig"}**), this leads to a large difference in signal between the two scans. By combining data from the two energy sets, these high Z materials can be differentiated from one another and quantified. This process is demonstrated in **Figure [13A](#F13){ref-type="fig"}**, which shows scans of an *in vitro* phantom containing vials of water, gold, iodine, or a mixture of gold and iodine. Scans at two different energies were simultaneously acquired. These two scans were then mathematically decomposed into a map of iodine concentration and a map of gold concentration ([@B43]). We note that although the K-edges have helped with the separation between iodine and gold, we are not able to deliver true K-edge imaging as is possible with synchrotron mono-energetic beams.

![**Dual energy micro-CT material decomposition.** **(A)**, *In vitro* phantom consisting of a large tube of water surrounded by vials containing gold, iodine, or a mixture of the two. **(B)**, *In vivo* imaging of gold nanoparticles and iodine-containing liposomes within a mouse soft tissue sarcoma. The iodine (shown in red) and gold (shown in green) maps are the result of dual energy decomposition. In both cases, the decomposition was able to successfully differentiate the signals from the gold and iodine contrast agents.](fphar-06-00256-g013){#F13}

Spectral separation using DE CT is somewhat limited by our ability to minimize the overlap of x-ray spectra using polychromatic sources. Although the peak tube voltage can be changed over a wide range, the average energy of the resulting spectrum does not change significantly, as was shown for the two energy spectra in **Figure [2A](#F2){ref-type="fig"}.** The separation between the two energy spectra can be improved by applying additional filtration to the x-ray tubes, which can preferentially remove low energy photons and further increase the average energy of the x-ray spectrum. The other limitation for DE CT is its ability to discriminate between closely related elements. Discrimination of two elements using DE CT is best when there is a large difference in their attenuations at the two x-ray energies. This works very well for elements with widely different k-edges (gold and iodine), but does not work for elements with very similar k-edges (barium and iodine). By careful selection and design of contrast agents, this limitation can be avoided.

Although DE CT is commonly used in the clinic, its use has been limited to date in preclinical micro-CT imaging. The primary challenge with translating CT to micro-CT is the significant increase in resolution. Because voxel size is much smaller, the noise is much higher for micro-CT than for clinical CT. This could be improved by significantly increasing the number of x-ray photons delivered in order to get the same photon flux through each voxel. However, the radiation dose must be limited for *in vivo* studies, so noise cannot be decreased to the levels seen in clinical scans. This presents a problem for DE reconstruction, because the mathematical decomposition of multiple materials depends on having high quality (low noise) measurements of attenuation at each voxel. High levels of noise make material decomposition inaccurate. By minimizing scatter during acquisition and applying post-acquisition image processing strategies, beam hardening and noise can be reduced to allow for successful DE decomposition. It has been shown that applying joint domain bilateral filtration (an edge-preserving, smoothing filter that incorporates data from both energy sets) prior to DE decomposition significantly improves the DE decomposition accuracy, precision, and limits of detectability ([@B43]). The mean limits of detectability for each element were determined to be 2.3 mg/mL (18 mM) for iodine and 1.0 mg/mL (5.1 mM) for gold, well within the observed *in vivo* concentrations of each element (I: 0--24 mg/mL, Au: 0--9 mg/mL) and a factor of 10 improvement over the limits without post-reconstruction joint bilateral filtration. *In vitro* testing of this method using imaging phantoms containing both gold and iodine is shown in **Figure [13A](#F13){ref-type="fig"}** ([@B43]). Using this method, DE micro-CT has been used successfully for a variety of applications in mice. DE CT was used for atherosclerosis imaging to differentiate liposomal iodine accumulated in plaque macrophages from calcium within the plaque ([@B28]). Iodine accumulated within the myocardium has been separated from other soft tissues and from calcium in the bone for imaging of myocardial infarction ([@B12]). DE CT has been used to separate gold nanoparticles accumulated within soft-tissue sarcomas ([@B43]) or primary lung tumors ([@B13]) from liposomal iodine within the vasculature. Images of the decomposed gold and iodine maps for a soft-tissue sarcoma are shown in **Figure [13B](#F13){ref-type="fig"}.** In these studies, the simultaneous measurement of two different nanoparticle concentrations was used to calculate tumor vascular density and vascular permeability. Validation of the calculated results was performed using histology and *ex vivo* measurements of tissue gold and iodine concentrations ([@B13]). In two additional studies, DE CT was used to assess vascular changes following radiation therapy. In the first, the increase in vascular permeability in a soft-tissue sarcoma was determined by measuring accumulation of liposomal iodine ([@B129]). In the second study, cardiac injury following radiation therapy was assessed using gold nanoparticles and liposomal iodine ([@B110]). Cardiac-gated CT imaging was performed to obtain a DE decomposition of the myocardium at each phase of the cardiac cycle. This data was used to assess both extent of cardiac injury and change in cardiac function.

Our group has recently also demonstrated triple-energy micro-CT for the differentiation of three materials: gold, iodine, and gadolinium. Using a novel algorithm called spectral diffusion ([@B42]), these three materials were successfully separated and quantified both in an *in vitro* phantom and *in vivo.* **Figure [14](#F14){ref-type="fig"}** shows *in vivo* images with decomposed concentration maps depicting liposomal iodine accumulated within the liver and spleen, gold nanoparticles within the vasculature, and a low molecular weight gadolinium contrast agent in the kidneys. Dual and triple-energy CT have the potential to be particularly useful with targeted contrast agents, so that contrast agents with multiple different targets can be co-injected and individually quantified using a single scan.

![**Three-energy micro-CT imaging in a mouse.** Liposomal iodine was injected 72 h before imaging. Gold nanoparticles and low molecular weight gadolinium were injected immediately before imaging. Images were acquired at three energies, filtered, then separated into maps of iodine (red), gold (green), and gadolinium (blue) concentration.](fphar-06-00256-g014){#F14}

Photon Counting X-ray Detectors
-------------------------------

The alternative to DE CT is the use of energy-resolving photon-counting x-ray detectors (PCXDs) for spectral CT imaging. The PCXDs acquire data for each projection using multiple energy bins. These detectors directly convert photons to a digital signal, which decreases the noise that is inherent in traditional energy-integrating detectors ([@B164]). Each photon that is counted by the detector is assigned into one of the energy bins, which provides an approximation of the energy spectrum of the transmitted x-rays. Energy bins can be chosen to include regions of the spectrum above and below the K-edge of the elements of interest. The measured attenuations from each energy bin can then be used to simultaneously solve for the concentration of one or more high atomic weight materials within a single voxel. This method can also be used quantify the contribution of either Compton scattering or the photoelectric effect within any given voxel, which allows accurate separation between signal from soft tissues and signal from high Z materials.

Photon-counting x-ray detectors are not yet used in standard clinical CT imaging, but prototype photon counting CT scanners have been deployed in some research hospitals. It is expected that PCXDs will likely be generally adopted in the clinical realm once the technology has further advanced ([@B172]). The primary drawback of current PCXDs is the relatively low photon count rate for each individual detector. Because it takes a finite amount of time to count a single photon, the hardware can fall behind when photon flux is high. This leads to pulse pileup, which can cause saturation of the detectors and loss of spectral sensitivity and accuracy ([@B164]). Clinical CT operates at very high photon flux, so this problem must be resolved before PCXDs can be effectively used clinically. The most obvious solution is to decrease the detector size, which will decrease the flux incident on each detector. However, as detectors become smaller, the charge sharing between detectors increases, which can lead to multiple counts for single x-rays and counts at the wrong energies. This leads to spectral distortions and high noise. Therefore, many researchers are focused on improving both the hardware and reconstruction algorithms necessary for optimal spectral imaging with PCXDs.

Although PCXDs are still experimental for clinical CT, their use in preclinical small animal studies has been successfully demonstrated. Spectral CT has been used with targeted nanoparticles to image atherosclerotic plaques ([@B46]). Gold nanoparticles were encapsulated within high-density lipoprotein (HDL) particles to target plaque macrophages. A preclinical spectral CT system (Phillips Research, Hamburg) was used to differentiate the gold from iodine, calcium, and soft tissues. This analysis was first performed in an *in vitro* aorta phantom, as shown in **Figure [15A](#F15){ref-type="fig"}.** Spectral CT was used to resolve the signals from gold, iodine and calcium within the tissue phantom matrix. The spectral CT system successfully differentiated the phantom regions containing gold, iodine, and calcium, with very little overlap between the signals. They also tested the targeting of their gold-HDL particles in a mouse model of atherosclerosis. Spectral CT (and subsequent histology) demonstrated that the gold successfully accumulated within the plaques and that gold could be discriminated from iodine, calcium, and soft-tissue *in vivo*, as seen in **Figure [15B](#F15){ref-type="fig"}.** The same HDL-encapsulated gold nanoparticles have been used along with a blood pool iodine contrast agent to simultaneously image the signals from gold accumulated within lymph nodes, iodine within the blood, bone, and soft tissue ([@B154]). Low density-lipoproteins (LDLs) labeled with gold nanoparticles have also been used to image tumors using spectral CT ([@B2]). Gold nanoparticles accumulating in lymph nodes after subcutaneous injection have been differentiated from soft tissue and bone ([@B165]). Iodine within the vasculature and barium within the gastrointestinal tract have been imaged and differentiated from bone and soft tissue ([@B6]). Spectral imaging has also been used to detect novel ytterbium nanoparticles within the vasculature ([@B141]) and organic bismuth nanocolloids targeted to fibrin-rich clots ([@B140]). In both cases, spectral CT was used to differentiate contrast agent signal from soft tissue and bone. The primary limitation in all of these studies was that the low photon-count rate limitations of the PCXD system resulted in a long scan time. Because the scan time was so long, the imaging was done after sacrificing the animals in order to prevent motion over the course of the long acquisition. Despite the limitations, these studies demonstrate that spectral CT using a PCXD system has the potential for high quality *in vivo* imaging and material discrimination. Some technical problems remain to be solved, but PCXD systems have great promise for use in both preclinical and clinical CT imaging.

![**Spectral micro-CT imaging using photon counting x-ray detectors and HDL-encapsulated gold nanoparticles.** **(A)** In vitro aorta phantom study demonstrating the conventional CT image along with the decomposition of the CT image into gold, iodine, photoelectric, and Compton components. **(B)** *In vivo* imaging of targeted gold nanoparticles and blood pool iodine in a mouse model of atherosclerosis. The iodine (red) can be clearly visualized within the aorta, while the gold signal (yellow) is immediately adjacent to the aorta lumen in the atherosclerotic plaque. Reprinted with permission from ([@B46]).](fphar-06-00256-g015){#F15}

Radiation Dose Considerations
=============================

One of the primary drawbacks of x-ray CT imaging is exposure to radiation. X-ray radiation exposure can lead to biological damage and long-term health effects ([@B31]). Radiation exposure is particularly important to consider for micro-CT applications, because higher radiation doses are required for high resolution CT scans. Signal-to-noise ratio in CT is inversely proportional to the square root of the number of x-rays passing through each voxel. As voxel size decreases, the number of x-rays necessary to maintain a constant signal-to-noise ratio increases significantly. In planning micro-CT studies, a balance must be made between desired image quality and radiation exposure.

The LD~50/30~ radiation dose in mice (the dose required to kill 50% of mice within 30 days) depends on many factors, but tends to be between 5 and 8 Gy ([@B152]; [@B34]). The typical radiation dose for a single micro-CT scan can vary widely and reported values in the literature range from 0.017 Gy to 0.78 Gy ([@B34]). Rodents have the ability to repair damage from low doses of radiation (∼0.3 Gy) over the course of several hours ([@B143]), so most low dose micro-CT scans should have limited biological impact, even when the same animals are longitudinally scanned over the course of a study. But for higher dose scans, longitudinal imaging can potentially lead to a cumulative dose that could affect biological function (particularly immune function and tumor response) and long-term health ([@B31]). Therefore, careful consideration must be made to determine the optimal imaging protocol for each individual application to minimize the effects of radiation dose on the experiment. With additional advances in micro-CT technology and reconstruction algorithms, radiation doses should further decrease, which will help to overcome radiation as a limitation of micro-CT imaging.

Nanoparticle Contrast Agent Safety
==================================

Understanding the potential toxicity of nanoparticles is essential in order to apply nanoparticle contrast agents *in vivo* and eventually translate these contrast agents to the clinic. Because blood pool contrast agents are not rapidly cleared from the body by the kidneys, they have much more opportunity to interact with the body and accumulate in various organs. Since each nanoparticle formulation is unique, rigorous toxicity testing must be performed for any proposed contrast agent in order to fully understand its usefulness for both preclinical research and potential clinical translation. For example, there is strong evidence regarding bio-compatibility of gold ([@B36]; [@B79]; [@B120]). Gold-based nano-products are now undergoing clinical trials, e.g., colloidal Au-based tumor necrosis factor (CYT-6091, CytImmune, Inc., Rockville, MD, USA) and gold nanoshells (Nanospectra, Inc., Houston, TX, USA). However, there is still uncertainty regarding the toxicity of many of the recently proposed nanoparticle contrast agents; although most of the studies reviewed here have stated that no toxicity has been observed, comprehensive prospective toxicity studies are still required to be performed. Because many nanoparticles can accumulate in the body for up to several months, in depth studies of long term toxicity are particularly important. A better understanding of nanoparticle toxicity is necessary for the further advancement of the field of nanoparticle CT contrast agents.

Conclusion
==========

Micro-CT has become an extremely important tool in small animal research. Micro-CT produces non-invasive, three-dimensional, high resolution anatomical images, which can provide a wealth of information about normal animal function and pathology. Although x-ray CT is limited by low tissue contrast, developments in contrast agent design show great promise for use in imaging a wide range of organ systems and pathologies. Additional new developments in spectral imaging will further improve the usefulness of micro-CT in acquiring functional and molecular information. This will greatly expand the potential applications for micro-CT in small animal research. The increasing availability and low cost of micro-CT scanners promises to greatly increase the use and impact of micro-CT imaging on small animal studies. Given the common use of mouse models of disease to validate potential drug targets, to assess therapeutic efficacy, and to identify and validate biomarkers of drug efficacy and/or safety, micro-CT with nanoparticle based contrast agents can have far-reaching applications in drug discovery and pharmacology. Continuous development of novel CT/micro-CT imaging technology and contrast agents will serve well drug discovery and result in better medicines. Contrast agents and technology developed for preclinical micro-CT also have the potential to translate to significant improvements in clinical CT imaging.
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